Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GSK and University of Nottingham Collaborate to Create Centre of Excellence for Sustainable Chemistry

Published: Friday, April 27, 2012
Last Updated: Friday, April 27, 2012
Bookmark and Share
Innovative carbon neutral laboratory to be established on University Campus.

GlaxoSmithKline (GSK) and The University of Nottingham have formalized a collaboration to establish a new laboratory to accommodate a Centre of Excellence for sustainable chemistry, and to construct an innovative carbon neutral sustainable chemistry laboratory.

This agreement represents progress on GSK’s ‘green chemistry’ commitment first announced in 2010.

The GlaxoSmithKline Carbon Neutral Laboratory for Sustainable Chemistry will be based on the University’s Jubilee Campus and its construction is being supported by a £12m grant from GSK.

The laboratory will be a Centre of Excellence for sustainable chemistry and will focus on research that is of particular relevance to the pharmaceutical industry and which complements established expertise at the University of Nottingham.

It will also deliver advanced undergraduate teaching and outreach to the wider scientific community to embed sustainable chemistry principles in the next generation of scientists.

The Centre of Excellence will serve as a global hub to catalyze new collaborations with other institutions and industry partners and will bring together leading UK academics, postgraduate and postdoctoral researchers and GSK chemists, developing expertise in sustainable chemical synthesis.

The focus on sustainability will be reflected in the building itself, which will incorporate the latest technologies to allow it to be carbon-neutral over its lifetime.

The laboratory will be built from natural materials and energy required to run the laboratory will be met by renewable sources such as solar power and sustainable biofuel.

Excess energy created by the building will provide enough carbon credits over 25 years to pay back the carbon used in its construction.

Sir Andrew Witty, CEO of GSK said: “The carbon neutral laboratory will help affirm the UK as a global hub for the future of the life-sciences industry. Our vision is that the science researched within the laboratory will be as iconic as the building itself. This is an opportunity to invest further in science in the UK, re-think how we approach the drug discovery process and play a role in contributing to environmental stewardship.”

Professor David Greenaway, Vice-Chancellor of The University of Nottingham, said: “This development will be transformational in several dimensions: the built form will break new ground in sustainable construction; the Centre of Excellence will shape the future of drug discovery; and innovation in training and development will accelerate the translation of discovery to application. This is all tremendously exciting and will underpin a unique partnership between GSK and the University of Nottingham.”

Today’s announcement builds on GSK’s environmental strategy announced in 2011, with an objective that the company’s operations will become carbon neutral by 2050.

Adopting sustainable chemistries from the start of the drug discovery process will help to reduce the impact of both the discovery and subsequent manufacturing of drugs on the environment, whilst optimizing the use of increasingly scarce natural resources.

GSK will also fund a research programme to gather information on aspects of the carbon neutral laboratory that could be transferred into the existing GSK estate to increase efficiency, reduce energy consumption and carbon emissions.

Minister for Universities and Science David Willetts said: “This new laboratory is an excellent example of collaboration between universities and industry. It shows how businesses can benefit from the knowledge and expertise of our world leading research base and will help keep us at the very forefront of life sciences.”

GSK’s donation is a key contribution to the University’s fundraising campaign, a five-year drive to raise £150m, launched in October 2011. ‘Impact: The Nottingham Campaign’ focuses around the five themes of Sustainable Futures, Health & Wellbeing, Ingenuity, Nurturing Talent and the Nottingham Experience.

The University of Nottingham is renowned for its scientific excellence, with a broad portfolio of chemistry-based degree courses.

GSK has a number of existing relationships with the University including providing support through postgraduate chemistry studentships, delivering a medicinal chemistry module to third year undergraduate chemists and offering opportunities for fourth year MSci project students to participate in live GSK research programmes.

The University continues to provide GSK with high quality chemists for industrial placements, graduate and postgraduate roles.

Christopher Moody, Sir Jesse Boot Professor of Chemistry at University of Nottingham, said: “The carbon neutral laboratory is an outstanding opportunity to put in place an innovative new research training framework and develop an ethos for sustainable synthesis that will be unique in the UK. We will investigate new methods to address problems in synthetic chemistry, whilst building a greater awareness of the environmental impact of choice of solvents, reagents and procedures.”

Construction of the laboratory will begin in the spring of 2013 and it is expected to be completed during 2014.

It will be one of the first laboratory buildings designed to Building Research Establishment Environmental Assessment Method (BREEAM) ‘Outstanding’ standard, and will be located on the University’s Jubilee Campus - an exemplar of brownfield regeneration, with buildings that demonstrate best practice in renewable energy technologies and environmentally-friendly design.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK, UNC-Chapel Hill Launch $20M HIV Partnership
This new collaboration will be focused on curing HIV through a jointly-owned new company and a research center.
Tuesday, May 12, 2015
GSK to Establish Global Vaccines R&D Centre in the US
New hub based in Rockville, MD expands GSK’s global vaccines R&D footprint.
Thursday, April 09, 2015
GSK Awarded Up to $200 Million by U.S. Government to Develop New Antibiotics
Funding will support development of drugs to fight antibiotic resistance and bioterrorism.
Friday, May 24, 2013
GSK Launches Discovery Fast Track Competition for Academic Researchers
Scientists in U.S., Canada challenged to submit groundbreaking research proposals for chance at collaborative partnership focused on drug discovery.
Wednesday, May 22, 2013
GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
Both Companies end collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
Tuesday, May 07, 2013
GSK and Impax Terminate Their Collaboration
The companies are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.
Tuesday, April 30, 2013
FDA Approves GlaxoSmithKline’s Four-Strain Seasonal Influenza Vaccine for Use in the US
FLUARIX® QUADRIVALENT is for the immunisation of children (3+) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
Thursday, December 20, 2012
GSK and GlaxoSmithKline Consumer Nigeria PLC Announces Agreement
GSK to increase its stake in GlaxoSmithKline Consumer Nigeria PLC.
Friday, November 30, 2012
GSK Agrees in Principle to Increase its Stake in GlaxoSmithKline Consumer Nigeria PLC
GSK plc and GSK Consumer Nigeria PLC announced that they have reached agreement in principle on the terms of a proposal whereby GSK would increase its ownership in the Company from 46.4% to 80%.
Monday, November 26, 2012
GSK to acquire Human Genome Sciences for US$14.25 per Share in Cash
GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib. Acquisition will be accretive to GSK core earnings in 2013.
Monday, July 16, 2012
GSK to Fully Acquire Cellzome for £61 Million
GSK to further expand its platform technology expertise with acquisition of chemical proteomics company.
Wednesday, May 16, 2012
GSK and Theravance Announce Progression of LAMA/LABA Combination Treatment Into Phase III Development for COPD
Relovair™ programme expanded by start of large Phase IIIb COPD outcomes study.
Friday, February 04, 2011
GlaxoSmithKline and Theravance Commence MABA Phase IIb COPD Study
GlaxoSmithKline (GSK) and Theravance (NASDAQ: THRX) announced today that the first patient has started treatment with an investigational inhaled bifunctional compound GSK961081 ('081) in a Phase IIb study to evaluate efficacy and safety in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Wednesday, December 22, 2010
GlaxoSmithKline in Pioneering Collaboration with The University of Nottingham
A new facility focused on the development of ‘green chemistry’ technology is part of a pioneering new partnership.
Wednesday, December 01, 2010
New Partnership to Focus on 'Green Chemistry'
A new facility focused on the development of ‘green chemistry’ technology is part of a pioneering new partnership between GlaxoSmithKline and The University of Nottingham, announced on November 29 2010.
Tuesday, November 30, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!